(Q36471827)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jonathan Cebon

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Theo Nicholaou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Ian D Davis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Neil Robson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Oliver Klein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Eugene Maraskovsky

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Weisan Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

Immunology & Cell Biology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

303-317

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

The DNA sequence of the human X chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Epigenetic immunomodulation of hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

LAGE-1, a new gene with tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 expression and immunogenicity in esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Autoreactive T cells in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

B-cell epitopes from the cancer testis antigen NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Antigen-specific regulatory T cells--their induction and role in infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

ISCOM based vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Valpha14 NKT cell-mediated anti-tumor responses and their clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

T-cell regulation by CD28 and CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Transformation of the microvascular system during multistage tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Immune cell migration in inflammation: present and future therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Expression of serologically identified tumor antigens in acute leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

NY-ESO-1 protein expression and humoral immune responses in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01446.X

10.1111/J.1440-1711.2006.01446.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16681828%20AND%20SRC:MED&resulttype=core&format=json

release_cpxjjgeynvhpvbrznv3yjwm6hm

20 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cpxjjgeynvhpvbrznv3yjwm6hm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference